Oragenics Inc financial data

Symbol
OGEN on NYSE
Industry
Pharmaceutical Preparations
Location
1990 Main Street, Suite 750, Sarasota, FL
State of incorporation
FL
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Mar 14, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 514 % -57.9%
Debt-to-equity 89.5 %
Return On Equity -620 % -104%
Return On Assets -327 % -32.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.5M shares +379%
Common Stock, Shares, Outstanding 12.6M shares +308%
Entity Public Float 4.74M USD -29.3%
Common Stock, Value, Issued 12.6K USD +308%
Weighted Average Number of Shares Outstanding, Basic 6.62M shares +194%
Weighted Average Number of Shares Outstanding, Diluted 6.62M shares +194%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 37.7K USD -71.4%
Research and Development Expense 4.11M USD -73.4%
General and Administrative Expense 6.44M USD +18.2%
Operating Income (Loss) -10.6M USD +49.5%
Nonoperating Income (Expense) -9.1K USD -104%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -10.6M USD +48.8%
Net Income (Loss) Attributable to Parent -10.6M USD +48.8%
Earnings Per Share, Basic -1.6 USD/shares +82.6%
Earnings Per Share, Diluted -1.6 USD/shares +82.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 865K USD -75.2%
Assets, Current 1.47M USD -61.9%
Property, Plant and Equipment, Net 0 USD -100%
Operating Lease, Right-of-Use Asset 9.81K USD -97.2%
Assets 1.47M USD -70.4%
Accrued Liabilities, Current 203K USD -8.94%
Liabilities, Current 1.8M USD +12.6%
Operating Lease, Liability, Noncurrent 65.8K USD -69.7%
Liabilities 1.68M USD -6.33%
Retained Earnings (Accumulated Deficit) -217M USD -5.13%
Stockholders' Equity Attributable to Parent -212K USD -107%
Liabilities and Equity 1.47M USD -70.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.06M USD -45.3%
Net Cash Provided by (Used in) Financing Activities 1.65M USD
Common Stock, Shares Authorized 350M shares 0%
Common Stock, Shares, Issued 12.6M shares +308%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.41M USD +37.8%
Interest Paid, Excluding Capitalized Interest, Operating Activities 7.09K USD +112%
Deferred Tax Assets, Valuation Allowance 48.4M USD +3%
Deferred Tax Assets, Gross 48.4M USD +3%
Operating Lease, Liability 9.81K USD -97.3%
Lessee, Operating Lease, Liability, to be Paid 9.89K USD -97.4%
Property, Plant and Equipment, Gross 1.48M USD
Operating Lease, Liability, Current 9.81K USD -95.2%
Lessee, Operating Lease, Liability, to be Paid, Year One 9.89K USD -95.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 381 USD -98.4%
Deferred Tax Assets, Operating Loss Carryforwards 41.1M USD +3.16%
Preferred Stock, Shares Issued 7.49M shares -55.9%
Preferred Stock, Shares Authorized 50M shares 0%
Unrecognized Tax Benefits 4.04M USD -3.06%
Operating Lease, Payments 59.3K USD +1.26%
Additional Paid in Capital 217M USD +4.22%
Preferred Stock, Shares Outstanding 7.49M shares -55.9%
Share-based Payment Arrangement, Expense 516K USD -6.19%
Interest Expense 34.3K USD +126%